Header Forschung

Department of Medicine I

The Department of Medicine I (Med. Klinik und Poliklinik I) includes the disciplines hematology/oncology, gastroenterology, pneumology and intensive care. The main focuses of research are hematologic malignancies, solid tumors and immunotherapy. 

Dresden is the coordinating center of a nationwide clinical study group (Study Alliance Leukemia). Within the mentioned consortium, novel pharmacological and cellular therapies are developed within phase I to III clinical trials. This is achieved either within independent investigator-initiated or industry sponsored clinical trials. Novel combination therapies are studied in multi-institutional trials and a dedicated early clinical trial unit. A major strength within the department is the area of hematopoietic stem cell transplantation and adoptive immunotherapy. In addition, Dresden PIs have been successful in establishing novel molecular biomarkers for therapy guidance and have recently embarked on collaborations in the area of functional drug screening. 

The area of oncology is dedicated to GI cancer with a specific focus on colorectal and pancreatic cancer. Dresden PIs are representatives of internationally active study groups in both of these disease entities. Key discoveries include the introduction of novel chemo-immunotherapeutic approaches.

Within the department novel immunotherapeutic strategies employing bispecific antibodies and genetically modified T cells are developed for first-in-man applications together with the department of immunology, department of radiopharmaceutics and local start-up companies.

Mitroulis I, Kalafati L, Bornhäuser M, Hajishengallis G, Chavakis T.
Regulation of the Bone Marrow Niche by Inflammation. Front Immunol. 2020 Jul
21;11:1540. doi: 10.3389/fimmu.2020.01540. PMID: 32849521; PMCID: PMC7396603.

Röllig C, Kramer M, Schliemann C, Mikesch JH, Steffen B, Krämer A, Noppeney R, Schäfer-Eckart K, Krause SW, Hänel M, Herbst R, Kunzmann V, Einsele H, Jost E, Brümmendorf TH, Scholl S, Hochhaus A, Neubauer A, Sohlbach K, Fransecky L, Kaufmann M, Niemann D, Schaich M, Frickhofen N, Kiani A, Heits F, Krümpelmann U, Kaiser U, Kullmer J, Wass M, Stölzel F, von Bonin M, Middeke JM, Thiede C, Schetelig J, Berdel WE, Ehninger G, Baldus CD, Müller-Tidow C, Platzbecker U, Serve H, Bornhäuser M. Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia? Blood. 2020 Aug 13;136(7):823-830. doi: 10.1182/blood.2019004583. PMID: 32496541

Vadakekolathu J, Minden MD, Hood T, Church SE, Reeder S, Altmann H, Sullivan AH, Viboch EJ, Patel T, Ibrahimova N, Warren SE, Arruda A, Liang Y, Smith TH, Foulds GA, Bailey MD, Gowen-MacDonald J, Muth J, Schmitz M, Cesano A, Pockley AG, Valk PJM, Löwenberg B, Bornhäuser M, Tasian SK, Rettig MP, Davidson-Moncada JK, DiPersio JF, Rutella S. Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia. Sci Transl Med. 2020 Jun 3;12(546):eaaz0463. doi: 10.1126/scitranslmed.aaz0463. PMID: 32493790; PMCID: PMC7427158.

Schetelig J, Baldauf H, Heidenreich F, Massalski C, Frank S, Sauter J, Stelljes M, Ayuk FA, Bethge WA, Bug G, Klein S, Wendler S, Lange V, de Wreede LC, Fürst D, Kobbe G, Ottinger HD, Beelen DW, Mytilineos J, Fleischhauer K, Schmidt AH, Bornhäuser M. External validation of models for KIR2DS1/KIR3DL1-informed selection of hematopoietic cell donors fails. Blood. 2020 Apr 16;135(16):1386-1395. doi: 10.1182/blood.2019002887. PMID: 31932846; PMCID: PMC7162689.

Krüger T, Middeke JM, Stölzel F, Mütherig A, List C, Brandt K, Heidrich K, Teipel R, Ordemann R, Schuler U, Oelschlägel U, Wermke M, Kräter M, Herbig M, Wehner R, Schmitz M, Bornhäuser M, von Bonin M. Reliable isolation of human mesenchymal stromal cells from bone marrow biopsy specimens in patients after allogeneic hematopoietic cell transplantation. Cytotherapy. 2020 Jan;22(1):21-26. doi: 10.1016/j.jcyt.2019.10.012. Epub 2019 Dec 27. PMID: 31883948.

Fasslrinner F, Stölzel F, Kramer M, Teipel R, Brogsitter C, Morgner A, Arndt C, Bachmann M, Hänel M, Röllig C, Kotzerke J, Schetelig J, Bornhäuser M. Radioimmunotherapy in Combination with Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Multiple Myeloma. Biol Blood Marrow Transplant. 2020 Apr;26(4):691-697. doi: 10.1016/j.bbmt.2019.11.007. Epub 2019 Nov 12. PMID: 31730919.